BioCentury
ARTICLE | Strategy

Mountain climbing

How Novo Nordisk aims to return to higher operating income growth

March 25, 2017 12:41 AM UTC

U.S. pricing pressure on insulin and hemophilia products have caused Novo Nordisk A/S to guide for negative sales and operating profit growth for the first time ever. While newly launched diabetes and obesity products are growing at a good clip, they remain too small to return the Danish pharma to historical double-digit growth rates on their own.

Two years ago Novo began laying the groundwork for a more innovative R&D strategy to return the company to higher growth. ...

BCIQ Company Profiles

Novo Nordisk A/S